The Affiliated Hospital of Guiyang Medical College/The Affiliated Cancer Hospital of Guiyang Medical College/Guizhou Cancer Hospital
Welcome,         Profile    Billing    Logout  
 12 Trials 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jin, Feng
CLOVER, NCT03926091: Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer

Recruiting
3
2172
RoW
Docetaxel, docetaxel injection, Cyclophosphamide, Cyclophosphamide injection
Fudan University
Breast Cancer
11/24
11/25
NCT03321539: Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma

Active, not recruiting
3
216
RoW
CCRT+GP, Adjuvant GP, CCRT+PF, Adjuvant PF
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/22
12/25
NCT03574324: TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC

Recruiting
3
266
RoW
TPF+CCRT, Experimental group, CCRT+PF, Control group
Guiyang Medical University
Locally Advanced Nasopharyngeal Carcinoma
05/23
05/23
DIPPER, NCT03427827: PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

Active, not recruiting
3
450
RoW
Camrelizumab, SHR-1210
Sun Yat-sen University
Nasopharyngeal Neoplasms
02/24
02/26
NCT06239727: Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Recruiting
3
593
RoW
PD-1 blocking antibody, Camrelizumab, Gemcitabine, GEM, Cisplatin (80 mg/m2), DDP, Reduced-dose Intensity-modulated radiotherapy, Reduced-dose IMRT, Conventional-dose Intensity-modulated radiotherapy, Conventional-dose IMRT, Cisplatin (100 mg/m2), Capecitabine
Sun Yat-sen University, Jiangsu Hengrui Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
02/27
02/30
2021-FXY-452, NCT05211232: Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Active, not recruiting
3
450
RoW
Tislelizumab, BGB-A317, Placebo
Sun Yat-sen University, Cancer Hospital of Guizhou Province, Hunan Cancer Hospital, Wuzhou Red Cross Hospital, Affiliated Hospital of Guangdong Medical University
Nasopharyngeal Carcinoma
05/26
05/28
NCT03907826: PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients

Recruiting
3
212
RoW
PD-1 blocking antibody, JS001, GP, IMRT
Sun Yat-sen University
Recurrent Nasopharyngeal Carcinoma
12/25
12/28
NCT05340491: Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Recruiting
3
212
RoW
Toripalimab, JS001, Chemotherapy, GP, Intensity modulated radiotherapy, IMRT
Sun Yat-sen University
Nasopharyngeal Carcinoma
12/24
12/27
NCT06749899: QL1706 (IPD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Recruiting
3
580
RoW
QL1706, Gemcitabine, Cisplatin, Intensity-modulated radiotherapy
Sun Yat-sen University, Qilu Pharmaceutical Co., Ltd.
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
12/28
12/30
AK104-IIT-019, NCT05587374: Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Recruiting
3
418
RoW
Cadonilimab, PD-1/CTLA-4 bi-specific antibody, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Akeso Pharmaceuticals, Inc.
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
01/25
01/27
DIAMOND, NCT04907370: PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma

Active, not recruiting
3
540
RoW
PD-1 blocking antibody, PD-1 Blockade, Gemcitabine, GEM, Cisplatin (80mg/m2), DDP, Cisplatin (100mg/m2), Intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd.
Nasopharyngeal Carcinoma
05/25
05/27
NCT05979961: Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

Recruiting
3
454
RoW
IMRT and concurrent cisplatin, gemcitabine and cisplatin (Induction chemotherapy)
Sun Yat-sen University, First Affiliated Hospital of Guangxi Medical University, Zhongshan People's Hospital, Guangdong, China, Wuhan Union Hospital, China, Tongji Hospital, Guangzhou Panyu Central Hospital, Hunan Cancer Hospital, Cancer Hospital of Guizhou Province
Nasopharyngeal Carcinoma
09/26
09/29
NCT03351062: Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Recruiting
3
844
RoW
Tamoxifen, Tamoxifen citrate, Toremifene, fareston
Chinese Anti-Cancer Association, Fudan University, Henan Cancer Hospital, The First Hospital of Jilin University, Southwest Hospital, China, First Hospital of China Medical University, Guangdong Provincial People's Hospital, Harbin Medical University, First Affiliated Hospital of Chongqing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu Provincial People's Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Zhejiang Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Union hospital of Fujian Medical University, Hebei Tumor Hospital, Hunan Cancer Hospital, Affiliated Hospital of Qinghai University, Wuhan TongJi Hospital, Hainan People's Hospital, The Third Affiliated Hospital of Kunming Medical College., The Third Affiliated Hospital of Nanchang University
Breast Cancer Female
12/25
12/25
NCT05044897: A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC

Recruiting
2
30
RoW
SI-B001
Sichuan Baili Pharmaceutical Co., Ltd.
Head and Neck Squamous Cell Carcinoma
06/25
06/25
NCT05054439: A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC

Recruiting
2
30
RoW
SI-B001, Paclitaxel
Sichuan Baili Pharmaceutical Co., Ltd.
Head and Neck Squamous Cell Carcinoma
06/25
06/25
PLATINUM, NCT03984357: Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

Active, not recruiting
2
152
RoW
PD-1 blocking antibody, PD-1 blockade, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Bristol-Myers Squibb
Nasopharyngeal Carcinoma
04/24
03/26
NCT05039606: Clinical Study of Radiotherapy Combined With Nedaplatin Contrast and Cisplatin for the Treatment of Locally Advanced Head and Neck Squamous Carcinoma

Not yet recruiting
2
164
RoW
Nedaplatin, Cisplatin
Guiyang Medical University
Head and Neck Squamous Carcinoma
09/26
09/26
NCT04937283: Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

Recruiting
N/A
690
RoW
Segmentectomy with systemic lymph node dissection, Lobectomy with hilar and mediastinal lymph node dissection
Shanghai Pulmonary Hospital, Shanghai, China
Lung Adenocarcinoma
12/28
12/28

Download Options